Eli Lilly (LLY)

Executive Summary

Eli Lilly (NYSE: LLY) is a global pharmaceutical leader with a strong focus on diabetes, obesity, oncology, immunology, and neuroscience. The company's crown jewel is tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 receptor agonist that has demonstrated superior efficacy in type 2 diabetes and obesity, driving explosive revenue growth. Lilly's pipeline is among the most robust in the industry, with 2686 candidates across multiple modalities including small molecules, biologics, and gene therapies. Key late-stage assets include orforglipron (oral GLP-1), which could expand its metabolic franchise, and donanemab for early Alzheimer's disease, already approved but with potential label expansions. Lilly's commercial execution remains excellent, with Zepbound capturing significant market share in the obesity space. The company also continues to invest in next-generation therapies for cardiovascular disease, non-alcoholic steatohepatitis (NASH), and autoimmune conditions. With a market capitalization exceeding $1 trillion and a track record of successful launches, Lilly is well-positioned to sustain its growth trajectory. However, pricing pressures, competition from Novo Nordisk and other players, and pipeline setbacks remain risks. Overall, Lilly's innovation, scale, and financial strength make it a top-tier biopharma investment opportunity.

Upcoming Catalysts (preview)

• Q3 2026Tirzepatide Phase 3 Data in Heart Failure with Preserved Ejection Fraction (HFpEF) and/or Sleep Apnea80% success
• Q2 2026Orforglipron Oral GLP-1 Phase 3 Top-Line Results in Type 2 Diabetes and Obesity70% success
• Q3 2026FDA Decision on Lebrikizumab for Atopic Dermatitis (if not yet approved, otherwise use next-gen obesity drug) - Assuming pending: FDA decision on lebrikizumab for moderate-to-severe atopic dermatitis60% success